Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001982792 | SCV002222948 | uncertain significance | Renal cell carcinoma | 2022-11-07 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with MET-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 1445197). This variant is present in population databases (rs552953455, gnomAD 0.007%). This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 765 of the MET protein (p.Val765Ile). |
| Ambry Genetics | RCV002458862 | SCV002737635 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-06-07 | criteria provided, single submitter | clinical testing | The p.V765I variant (also known as c.2293G>A), located in coding exon 9 of the MET gene, results from a G to A substitution at nucleotide position 2293. The valine at codon 765 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |